TELA Bio, Inc.
NasdaqGM:TELA Voorraadrapport
Marktkapitalisatie: US$76.0m
TELA Bio Inkomsten in het verleden
Verleden criteriumcontroles 0/6 De winst van TELA Bio is gedaald met een gemiddeld jaarlijks percentage van -10.1%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 13.2%. De inkomsten zijn groeide met een gemiddeld percentage van 32.5% per jaar.
Belangrijke informatie
78.5%
Groei van de winst per aandeel
Medical Equipment Groei van de industrie 8.9% Inkomstengroei 32.5% Rendement op eigen vermogen n/a Nettomarge -60.5% Laatste winstupdate 30 Sep 2024
Recente prestatie-updates uit het verleden
TELA Bio, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 18
TELA Bio, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 23
First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023) May 10
TELA Bio, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
Full year 2023 earnings released: US$2.04 loss per share (vs US$2.72 loss in FY 2022) Mar 23
TELA Bio, Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 01
Toon alle updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely Nov 09 TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $40.04942 million. Oct 24
TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $40.04942 million.
TELA Bio, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 18
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33% Aug 19
TELA Bio, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 23 TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell Small Cap Completeness Index
Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet? Jul 03
TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors Jun 06
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now May 29
TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward May 23
TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer May 23
TELA Bio, Inc. Provides Revenue Guidance for the Year 2024 May 11
First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023) May 10
TELA Bio, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
TELA Bio, Inc., Annual General Meeting, Jun 04, 2024 Apr 20
TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR Apr 17
Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts Mar 24 TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX
Full year 2023 earnings released: US$2.04 loss per share (vs US$2.72 loss in FY 2022) Mar 23
Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA) Mar 08
TELA Bio, Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 01
Consensus EPS estimates fall by 215% Nov 16 TELA Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Nov 15
Price target decreased by 18% to US$14.40 Nov 12
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 10
TELA Bio, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 27
TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry? Oct 07
John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc Sep 29
TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery Aug 17
Consensus EPS estimates upgraded to US$0.57 loss Aug 17
Second quarter 2023 earnings: EPS exceeds analyst expectations Aug 10
TELA Bio, Inc. Reaffirms Revenue Guidance for Full Year 2023 Aug 10
Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult Jul 31
TELA Bio, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 13
Tela Bio, Inc. Reaffirms Earnings Guidance for the Full Year 2023 May 12
Insufficient new directors May 01
Consensus EPS estimates fall by 13%, revenue upgraded Mar 30
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 23
TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack Jan 10
Price target decreased to US$17.40 Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 12
Price target decreased to US$17.40 Nov 11
TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022 Nov 10
TELA Bio, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 28
TELA Bio, Inc. Announces Publication of 24-Month Bravo Study Results Demonstrating Benefits of Ovitex(R) Reinforced Tissue Matrix in Hernia Repair Oct 27
TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption Oct 02
Consensus forecasts updated Aug 18 TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $32 million. Aug 16
Tela Bio prices $32M common stock offering Aug 16
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 11
TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 11
Tela Bio, Inc. Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs Aug 05
TELA Bio, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 28
CFO & COO recently bought US$83k worth of stock Jun 09
TELA Bio, Inc. Provides Revenue Guidance for the Fiscal Year 2022 May 24
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 12
Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly? May 12
TELA Bio, Inc. Announces Revenue Guidance for the Full Year 2022 May 12
TELA Bio, Inc., Annual General Meeting, Jun 01, 2022 Apr 22
TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel Apr 19
TELA Bio, Inc. Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution Mar 05
TELA Bio - Follow Up With Management Jan 14
High number of new directors Dec 31
Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 3Q 2020) Nov 12
Our First Look At TELA Bio Nov 04
TELA Bio Plugging Away Oct 25
TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique Sep 15
Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 2Q 2020) Aug 12
TELA Bio, Inc. Provides Earnings Guidance for the Full Year 2021 Aug 12
High number of new directors Aug 01 TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell 3000E Index
Independent Director Adele Oliva has left the company Jun 09
Chief Financial Officer Nora Brennan has left the company Jun 05
TELA Bio (TELA) Investor Presentation - Slideshow May 26
TELA Bio, Inc. Initiates Bravo II Study of Ovitex for the Robotic Repair of Ventral Hernias May 20
TELA Bio, Inc. Provides Revenue Guidance for the Full Year of 2021 May 16
Hoe TELA Bio geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis NasdaqGM:TELA Opbrengsten, kosten en inkomsten (USD Millions ) Datum Inkomsten Inkomsten G+A Uitgaven R&D-uitgaven 30 Sep 24 69 -42 83 9 30 Jun 24 65 -42 81 10 31 Mar 24 63 -40 79 10 31 Dec 23 58 -47 75 10 30 Sep 23 53 -44 68 10 30 Jun 23 49 -44 65 9 31 Mar 23 45 -45 61 9 31 Dec 22 41 -44 57 9 30 Sep 22 38 -43 54 8 30 Jun 22 35 -40 50 7 31 Mar 22 32 -36 45 7 31 Dec 21 29 -33 42 7 30 Sep 21 27 -32 39 6 30 Jun 21 24 -32 38 6 31 Mar 21 20 -30 34 5 31 Dec 20 18 -29 32 4 30 Sep 20 17 -28 31 4 30 Jun 20 16 -27 28 3 31 Mar 20 16 -29 27 3 31 Dec 19 15 -30 24 4 30 Sep 19 13 -32 22 4 30 Jun 19 11 -30 21 5 31 Mar 19 10 -28 20 5 31 Dec 18 8 -30 19 4 31 Dec 17 4 -27 14 6
Kwaliteitswinsten: TELA is momenteel verliesgevend.
Groeiende winstmarge: TELA is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: TELA is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 10.1% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van TELA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: TELA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 11.7% ).
Rendement op eigen vermogen
Hoge ROE: De schulden van TELA zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
